1014 ET - The danuglipron setback has pushed Pfizer to the sidelines in the booming obesity market, but Viking Therapeutics' VK2735 could get the drugmaker back in the game, say analysts at William Blair. In a note, Andy Hsieh and Alexandra Ramsey say VK2735, in development as a pill and as an injection, could offer Pfizer a rare opportunity to reestablish not only a mere presence in obesity, but also a leading position beyond the current Novo Nordisk/Eli Lilly duopoly. With shares down significantly over the past six months, Viking sports a market cap of around $2.5 billion, but William Blair sees a fair value of $9.2 billion, or about $82 a share. Viking surges 9.7% to $24.43. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 10:14 ET (14:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。